Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study

The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Medicine (Baltimore)
Autors principals: Li, Yi-Hui, Zhou, Yang, Wang, Yu-Wei, Tong, Ling, Jiang, Run-Xue, Xiao, Lei, Zhang, Guang-Ju, Xing, Shu-Shan, Qian, Fang, Feng, Jing-Qi, Zhao, Ya-Ling, Wang, Jian-Gong, Wang, Xiao-Hong
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6133618/
https://ncbi.nlm.nih.gov/pubmed/30200142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000012222
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars